Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Monthly rFXIII in Congenital Factor XIII Deficiency
NCT00978380Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2009
- Primary completion
- Oct 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of catridecacog, sponsored by Novo Nordisk. Primary endpoint: Adverse Events (Serious and Non-serious) at 52 weeks. Started Sep 2009; status: completed.
02
Drugs
catridecacog
Beyond the preview
Go deeper on NCT00978380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00978380.